RESUMO
This JAMA Insights discusses the use of monoclonal antibodies or protein-based vaccines to help prevent severe RSV infection in infants, children, and older adults.
Assuntos
Antivirais , Infecções por Vírus Respiratório Sincicial , Vacinas contra Vírus Sincicial Respiratório , Humanos , Lactente , Antivirais/uso terapêutico , Palivizumab/uso terapêutico , Infecções por Vírus Respiratório Sincicial/tratamento farmacológico , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Recém-Nascido , Pré-Escolar , Idoso , Criança , Anticorpos Monoclonais Humanizados/uso terapêutico , Feminino , Gravidez , Adulto , Vacinas contra Vírus Sincicial Respiratório/uso terapêuticoRESUMO
Our national cross-sectional survey of United States hospitals found greater implementation of contact precautions for multidrug-resistant organisms and a higher percentage reporting the use of supplemental no-touch disinfection devices among Veterans Affairs (VA) versus non-VA hospitals. Nationally coordinated infection prevention initiatives within the VA could account for these practice differences.
Assuntos
Doenças Transmissíveis , Veteranos , Humanos , Estados Unidos , Estudos Transversais , Controle de Infecções/métodos , Hospitais , United States Department of Veterans Affairs , Hospitais de VeteranosRESUMO
Refugee and migrant populations have increased vulnerability to antimicrobial resistance, yet stewardship guidance is lacking. We addressed this gap through a cross-sectional survey, finding that these populations and immigrants from low and middle-income countries had lower health literacy on the issue compared to native-born Americans and those from high-income countries.
